Memo Therapeutics AG

The technological core of Memo Therapeutics is our droplet microfluidics based single-cell technology platform Dropzylla®. Dropzylla® provides an industry leading sensitivity and versatility in antibody and biologics discovery through its unparalleled efficiency in molecular cloning, expression and functional screening of complete antibody repertoires of human donors or immunized animals. Memo Therapeutics capitalizes on the Dropzylla® platform by developing technologies and candidate therapeutic antibodies for infectious diseases and cancer.